S.Korea's Celltrion surges; co's Remicade copy to be tested for COVID-19 treatment
** Drugmaker Celltrion Inc's 068270.KS shares rise as much
as 11.5% to their highest since March 2018
** Britain's University of Birmingham will test Remsima, the
biosimilar version of the anti-inflammatory drug Remicade
developed by Celltrion, it said on Wednesday, to see if the drug
could reduce the severity of COVID-19. urn:newsml:reuters.com:*:nL8N2DN230
** Celltrion's distribution affiliate, Celltrion Healthcare
091990.KQ saw shares rise as much as 12%
** The benchmark KOSPI market .KS11 was trading down 0.8%
(Reporting by Joyce Lee)
((jungyoon.lee@tr.com; +82 2 6936 1467;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap